Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
187 results
  • Ticagrelor in Patients with Stable Coronary Disease and Diabetes. [Journal Article]
    N Engl J Med 2019; 381(14):1309-1320Steg PG, Bhatt DL, … THEMIS Steering Committee and Investigators
  • CONCLUSIONS: In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, those who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. (Funded by AstraZeneca; THEMIS number, NCT01991795.).
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. [Randomized Controlled Trial]
    N Engl J Med 2019; 380(16):1509-1524Lopes RD, Heizer G, … AUGUSTUS Investigators
  • CONCLUSIONS: In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS number, NCT02415400.).
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. [Randomized Controlled Trial]
    N Engl J Med 2019; 380(4):347-357Wiviott SD, Raz I, … DECLARE–TIMI 58 Investigators
  • CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 number, NCT01730534 .).
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. [Randomized Controlled Trial]
    N Engl J Med 2018; 379(22):2097-2107Schwartz GG, Steg PG, … ODYSSEY OUTCOMES Committees and Investigators
  • CONCLUSIONS: Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES number, NCT01663402 .).
New Search Next